BRIEF published on 10/07/2026 at 08:26, 1 month ago Valerio Therapeutics: Review of the First Half of 2026 Financial Results Valerio Therapeutics Etherna Acquisition Abivax Collaboration InVimmune
BRIEF published on 08/24/2026 at 08:05, 2 months 14 days ago Valerio Therapeutics Acquires Etherna and Secures Financing Valerio Therapeutics Etherna Immunotherapies RNA Therapeutics Acquisition PIPE Financing Biotech Integration
PRESS RELEASE published on 08/24/2026 at 08:00, 2 months 14 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Valerio Therapeutics announces acquisition of Etherna Immunotherapies for €30 million enterprise value and €40.25 million PIPE financing. Shareholder approval secured Acquisition Valerio Therapeutics RNA Therapeutics Etherna Immunotherapies PIPE Financing
BRIEF published on 07/16/2026 at 09:12, 3 months 22 days ago Valerio Therapeutics and Abivax join forces for innovative therapies Abivax Collaboration Inflammatory Diseases Valerio Therapeutics RNA Therapies
BRIEF published on 07/16/2026 at 09:12, 3 months 22 days ago Valerio Therapeutics Partners with Abivax for RNA Therapeutics Development Biotechnology Valerio Therapeutics Pipelines RNA Therapeutics Abivax Collaboration
PRESS RELEASE published on 07/16/2026 at 09:07, 3 months 22 days ago Inside Information / Other news releases Valerio Therapeutics partners with Abivax for global collaboration, providing pipeline update on RNA therapeutics. Initial payment up to €2.4 million Abivax Collaboration Valerio Therapeutics Pipeline Update RNA Therapeutics
BRIEF published on 07/01/2026 at 09:27, 4 months 6 days ago Valerio Therapeutics Proposes to Acquire Etherna Immunotherapies Biotechnology Valerio Therapeutics Acquisition Deal RNA Medicines Etherna Immunotherapies
BRIEF published on 07/01/2026 at 09:27, 4 months 6 days ago Valerio Therapeutics is preparing to acquire Etherna Immunotherapies Valerio Therapeutics Biotechnology Investment Etherna Acquisition RNA Drugs Mergers Of Companies
PRESS RELEASE published on 07/01/2026 at 09:22, 4 months 6 days ago Inside Information / Other news releases Valerio Therapeutics announces binding offer to acquire Etherna Immunotherapies, creating global leader in targeted RNA medicines. Strategic move unlocked by leading investors Acquisition Valerio Therapeutics RNA Medicines Targeted Delivery Etherna Immunotherapies
BRIEF published on 06/16/2026 at 19:48, 4 months 21 days ago Valerio Therapeutics Appoints New CEO and Confirms AGM Resolutions Biotechnology CEO Transition Valerio Therapeutics Gilles Besin RNA Medicines
Published on 11/06/2026 at 22:15, 22 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 1 day 7 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 1 day 7 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 1 day 7 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/07/2026 at 13:35, 6 hours 40 minutes ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 1 day ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 1 day 1 hour ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 1 day 1 hour ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 1 day 1 hour ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 17:54, 1 day 2 hours ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 1 day 2 hours ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
